Dexamethasone eyedrop

PreclinicalSmall molecule

Dexamethasone eyedrop is one of 28 small molecule programs targeting Retinopathy of Prematurity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinopathy of PrematurityActive, not recruiting

Retinopathy of PrematurityPreclinical

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Retinopathy of Prematurity

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Approved

1 2

Ketalar

AAultman Health Foundation

Approved

1 3

Lucentis

Roche

Phase 3

4 4

Decadron

AAspen Global Incorporated

Eylea

3 6

Avastin

BBio-Thera Solutions

Phase 3

7 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 8

Eylea

Bayer

Phase 3

1 9

Inderal

WWyeth-Lederle Vaccines

Phase 2

5 10

Smoflipid

FFresenius

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinopathy of Prematurity1 trial

To Assess the Effect of Dexamethasone Eye Drops on the Retinopathy of Prematurity Outcome

Completed·RRegion Skane··NCT06775353·2,017 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dexamethasone eyedrop. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamethasone eyedrop compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamethasone eyedrop. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Region Skane company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRegion Skane

Dexamethasone eyedrop

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinopathy of Prematurity1 trial

References

Drug Info

Quick Facts

Related News